ArticleCurrent microbiology2014
Antibiofilm and antimicrobial efficacy of DispersinB®-KSL-W peptide-based wound gel against chronic wound infection associated bacteria.
Article in Current microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 99 citations in OpenAlex.
- Engineering host‑defense peptides enhanced by artificial intelligence and nano delivery systems to overcome biofilms and antimicrobial resistance.Engineering microbiology · 2026Review
- Periprosthetic joint infection after arthroplasty: advances and future prospects.Journal of orthopaedic surgery and research · 2025Review
- α-Amylase-Mediated Antibiotic Degradation and Sequestration inAntibiotics (Basel, Switzerland) · 2025Article
- Targeting Bacterial Biofilms on Medical Implants: Current and Emerging Approaches.Antibiotics (Basel, Switzerland) · 2025Review
- Pharmacological strategies for targeting biofilms in otorhinolaryngologic infections and overcoming antimicrobial resistance (Review).Biomedical reports · 2025Review
- Peptides in wound healing: A comprehensive review of their roles, challenges, and hydrogel-based delivery systems.EXCLI journal · 2025Review
- Periprosthetic joint infections: state-of-the-art.Archives of orthopaedic and trauma surgery · 2024Review
- Bioelectronic Drug-free Control of Opportunistic Pathogens through Selective Excitability.Device · 2024Article
- Review
- Current treatment strategies for targeting virulence factors and biofilm formation inFuture microbiology · 2024Review
- Lipid Nanocarriers-Enabled Delivery of Antibiotics and Antimicrobial Adjuvants to Overcome Bacterial Biofilms.Pharmaceutics · 2024Review
- Poly-Frontiers in microbiology · 2024Article
- Drug delivery strategies for antibiofilm therapy.Nature reviews. Microbiology · 2023Review
- Non-antibiotic prevention and treatment againstFrontiers in microbiology · 2023Review
- Current treatments for biofilm-associated periprosthetic joint infection and new potential strategies.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2022Review
- Novel Chronic Wound Healing by Anti-biofilm Peptides and Protease.Advanced pharmaceutical bulletin · 2022Review
- Bioactive Antimicrobial Peptides as Therapeutic Agents for Infected Diabetic Foot Ulcers.Biomolecules · 2021Review
- In vitro activities of cellulase and ceftazidime, alone and in combination against Pseudomonas aeruginosa biofilms.BMC microbiology · 2021Article
- Biofilms in Diabetic Foot Ulcers: Impact, Risk Factors and Control Strategies.International journal of molecular sciences · 2021Review
- Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The medical importance of bacterial biofilms has increased with the recognition of biofilms as one of the major contributors to the slow or non-healing chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Being a protected community of microorganisms, biofilms are notoriously refractory to antibiotic treatments. As the conventional treatment modalities have proven ineffective, this study provides the in vitro evidence to support the use of a novel combination of DispersinB(®) antibiofilm enzyme that inhibits biofilm formation and disperses preformed biofilm, and thus making the biofilm bacteria more susceptible to a broad-spectrum KSL-W antimicrobial peptide. The combination of DispersinB(®) and KSL-W peptide showed synergistic antibiofilm and antimicrobial activity against chronic wound infection associated biofilm-embedded bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Coagulase-negative Staphylococci (CoNS), and Acinetobacter baumannii. In addition, the wound gel formulation comprising DispersinB(®), KSL-W peptide, and a gelling agent Pluronic F-127 showed a broad-spectrum and enduring antimicrobial activity against test organisms. Furthermore, as compared to commercial wound gel Silver-Sept™, DispersinB(®)-KSL-W peptide-based wound gel was significantly more effective in inhibiting the biofilm-embedded MRSA, S. epidermidis, CoNS, Vancomycin-resistant Enterococci, A. baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa (P < 0.05). Thus, this study provides promising evidence for the potential application of antibiofilm-antimicrobial DispersinB(®)-KSL-W wound gel in chronic wound management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.